TL;DR
The FDA issued Import Alert 89-04 for certain medical devices made in Japan by Olympus Medical Systems Corporation and its subsidiaries, citing outstanding quality-system violations. The alert blocks future shipments of listed models from entering the United States; it does not apply to related replacement parts or consumables, and the FDA says devices already in use may remain in use if they are not experiencing problems.
The U.S. Food and Drug Administration said on October 20 that it has issued an import alert barring future U.S. entry of certain Olympus medical devices manufactured in Japan, citing outstanding violations of quality-system requirements. The alert, Import Alert 89-04, applies to specified models across several device categories and does not, by itself, direct health care providers to stop using affected devices already in service if they are working without problems.
The FDA said the alert covers listed models of bronchoscopes, ureterorenoscopes, laparoscopes, enteroscopes, automated endoscope reprocessors and ingestible telemetric gastrointestinal capsule imaging systems. The devices are used for diagnostic and therapeutic procedures in areas including the urinary and respiratory tracts, abdomen and pelvis, and small intestine. The agency points health care providers to a model-and-identifier table to determine whether a particular device is included.
According to the FDA, affected devices will be refused entry into the United States under the import alert because the agency continues to have concerns about outstanding quality-system regulation violations, despite what it described as Olympus’ extensive and ongoing efforts to address compliance issues. The notice says the alert concerns certain devices made in Japan by Olympus Medical Systems Corporation and its subsidiaries; it does not state that every Olympus product or every device made by the company is covered.
The FDA says the alert does not apply to related products used with listed devices, including replacement parts, connectors and single-use consumables. For devices already in use, the agency says providers may continue using them if they are not experiencing problems. It advises users to follow labeling and reprocessing instructions, avoid using damaged devices or devices that fail a leak test, and carry out routine inspections and maintenance according to the manufacturer’s instructions.
How the Alert Affects U.S. Care
The immediate effect is on future shipments of the listed models, not an across-the-board shutdown of Olympus devices already installed in U.S. facilities. The distinction matters for hospitals and clinics reviewing equipment inventories, procurement plans and the availability of replacement devices. Providers need to match model numbers and Unique Device Identifiers against the FDA list rather than assume a device is covered because it bears the Olympus name.
The notice also leaves clinical decisions with health care providers and patients. The FDA does not recommend canceling or delaying procedures automatically. It advises providers to discuss the benefits and risks of procedures involving the devices with patients. That direction recognizes that decisions may depend on a patient’s condition, the device involved and available alternatives; the notice does not provide a one-size-fits-all clinical instruction.
For facilities, the alert calls for attention to maintenance, cleaning and any product-specific recall instructions. The FDA says some devices covered by the alert may also have been recalled. If a device was recalled, users should follow the manufacturer’s customer notification letter for instructions. The import alert and any recall are separate matters, so providers should check the status of the particular model rather than assume the alert itself supplies recall directions.
Olympus bronchoscopes replacement parts
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Prior FDA Compliance Actions
The FDA describes the import alert as part of a wider history of regulatory action concerning Olympus quality-system compliance. The agency says it has previously issued warning letters and import alerts related to current good manufacturing practice requirements and various reporting requirements, including recalls that the FDA identified as the most serious type of recall. The notice does not detail each prior action or provide a full account of the underlying violations.
The device list in the notice identifies models and device identifiers, with the supplied table marking June 24, 2025 as the effective date for the listed devices. The FDA’s October 20, 2026 notice reiterates the alert and provides recommendations for health care providers. The agency says it is monitoring corrective actions related to ongoing quality violations and will share further information if it becomes available.
The FDA established the Unique Device Identification system to help identify medical devices sold in the United States from manufacturing through distribution and patient use. Providers can use the device identifier on a label and the agency’s AccessGUDID database to check product information. The source material provided for this report includes only part of the device table, so readers should consult the FDA’s current list for the complete set of affected models and identifiers.
“The FDA continues to have concerns related to outstanding Quality System regulation violations by Olympus.”
— U.S. Food and Drug Administration
gastrointestinal capsule imaging system
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Details Still Not Provided
The notice does not explain the specific quality-system violations that remain outstanding, describe each corrective action Olympus has taken, or say how long the import alert is expected to remain in effect. It also does not identify in the supplied material which listed devices, if any, are currently subject to recalls, or provide a complete recall-by-model account. The FDA advises providers to check the manufacturer’s recall notification when applicable.
The available source excerpt contains only part of the model and device-identifier table. It therefore cannot establish whether a particular device is covered unless its model appears in the complete FDA list. The notice also does not report how many devices or shipments may be affected, whether U.S. inventories are sufficient, or whether the agency has set a timetable for reviewing Olympus’ corrective actions.
The FDA’s statement that devices may continue to be used when they are not experiencing problems is not a finding that every device is free of risk. Providers are still advised to follow product instructions, avoid using damaged equipment or devices that fail leak tests, and report adverse events promptly. The notice does not specify a change to those recommendations for any individual patient or procedure.
As an affiliate, we earn on qualifying purchases.
Provider Checks and FDA Monitoring
Health care providers should compare each relevant device’s model number and device identifier with the FDA’s full import-alert table and consult AccessGUDID where needed. Facilities should also check whether a model has a separate recall notice and follow the instructions in any manufacturer notification. Routine inspection, maintenance and reprocessing should continue according to the device labeling and manufacturer guidance.
The FDA says it will continue monitoring Olympus’ corrective actions and will inform health care providers and the public if new or additional information becomes available. The agency has not announced a deadline for lifting the alert or a date for a further update. Any change in the import status, or new information about affected models or recalls, would need to come through subsequent FDA or manufacturer notices.
As an affiliate, we earn on qualifying purchases.
Key Questions
Which Olympus devices are covered by the import alert?
The alert applies to specified models of several device types, including bronchoscopes, ureterorenoscopes, laparoscopes, enteroscopes, automated endoscope reprocessors and capsule imaging systems. Check the FDA’s full model and device-identifier list; the alert does not cover every Olympus product.
Does the alert mean providers must stop using devices already in service?
No. The FDA says devices already in use may continue to be used if they are not experiencing problems. Providers should follow the device’s instructions and any separate recall notice, and should not use damaged devices or devices that fail a leak test.
Are replacement parts and consumables included?
The FDA says the import alert does not apply to related products such as replacement parts, connectors or single-use consumables used with the listed devices.
Should procedures involving the devices be canceled?
The FDA does not recommend automatic cancellation or delay. It advises health care providers to discuss the benefits and risks with patients before making decisions about procedures involving these devices.
Why did the FDA issue the alert?
The agency said it continues to have concerns about outstanding quality-system regulation violations at Olympus, despite the company’s ongoing efforts to address compliance issues. The notice does not detail the specific violations or set a date for ending the alert.
Source: primary
